search
Back to results

Enhancement of Macular Pigment Density by Oral Lutein Supplementation (EMPOLS)

Primary Purpose

Age-Related Maculopathies

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
VitaluxPlus®
Omega 3
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Age-Related Maculopathies focused on measuring age related macular degeneration, supplementation, macular pigment

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age related maculopathy

Exclusion Criteria:

  • exudative age related degeneration

Sites / Locations

  • Klinik und Poliklinik für Augenheilkunde, University Bern

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1

2

Arm Description

VitaluxPlus®

Omega 3

Outcomes

Primary Outcome Measures

Macular pigment density

Secondary Outcome Measures

contrast sensitivity

Full Information

First Posted
November 26, 2007
Last Updated
June 10, 2015
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT00563979
Brief Title
Enhancement of Macular Pigment Density by Oral Lutein Supplementation
Acronym
EMPOLS
Official Title
Enhancement of Macular Pigment Density by Oral Lutein Supplementation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®.
Detailed Description
The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®. Primary variable for a significant change will be 10% increase compared to baseline MPD. The measurement will be carried out by means of a modified confocal scanning laser ophthalmoscope (HRA) recording autofluorescence images at 488 nm and 514 nm 6. MPD is determined on MPD maps within 0.5 degrees around the center of the fovea. All MPD measurements and photographs will by performed by the Bern Photographic Reading Center (BPRC). Complete examination of study patients comprises testing of standardized visual acuity (ETDRS-VA), visual contrast sensitivity (CS), biomicroscopy, fundus photography, and a blood sample. Participating patients also have to fill out a food frequency questionnaire (FFQ-Bern) allowing for correction of additional lutein intake by regular diet. Moreover possible confounding factors e.g. as sunlight exposure or smoking habits will be assessed. Secondary objective of EMPOLS is the effect of oral non-compound ester lutein supplementation on CS and ETDRS-VA during one year. The variable for a significant change in ETDRS-VA is loss or gain of 7 letters on the ETDRS chart, for a change in CS: loss or gain of at least four letters on the Pelli-Robson CS Chart. Additionally, serum carotenoid levels of lutein will be determined by high performance liquid chromatography (HPLC) for each visit 1.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-Related Maculopathies
Keywords
age related macular degeneration, supplementation, macular pigment

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
VitaluxPlus®
Arm Title
2
Arm Type
Active Comparator
Arm Description
Omega 3
Intervention Type
Dietary Supplement
Intervention Name(s)
VitaluxPlus®
Intervention Description
1 tablet daily
Intervention Type
Dietary Supplement
Intervention Name(s)
Omega 3
Intervention Description
1 tablet daily
Primary Outcome Measure Information:
Title
Macular pigment density
Time Frame
6 months
Secondary Outcome Measure Information:
Title
contrast sensitivity
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age related maculopathy Exclusion Criteria: exudative age related degeneration
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sebastian Wolf, MD
Organizational Affiliation
University of Bern
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ute Wolf-Schnurrbusch, MD
Organizational Affiliation
University of Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinik und Poliklinik für Augenheilkunde, University Bern
City
Bern
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
26720458
Citation
Wolf-Schnurrbusch UE, Zinkernagel MS, Munk MR, Ebneter A, Wolf S. Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8069-74. doi: 10.1167/iovs.15-17586.
Results Reference
derived

Learn more about this trial

Enhancement of Macular Pigment Density by Oral Lutein Supplementation

We'll reach out to this number within 24 hrs